US EditionGLP-1 Receptor Agonists Linked to Reduced Uveitis Risk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Cleveland – GLP-1 RAs (glucagon-like peptide receptor agonists) may reduce the risk of non-infectious uveitis. Compared with no therapy, the risk was reduced by more than 50% with GLP-1 RAs. However, the study, now published in JAMA Ophthalmology (2025; DOI: 10.1001/jamaophthalmol.2025.2822), may be subject to bias...
GLP-1 Receptor Agonists Linked to Reduced Uveitis Risk
A new cohort study published in JAMA Ophthalmology suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used for managing diabetes and obesity, may be associated with a lower risk of uveitis compared with matched controls.[1] These findings hint at potential anti-inflammatory effects of GLP-1 RAs beyond their metabolic benefits, offering an avenue for future research into ocular inflammatory disorders. The retrospective co…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
